An Efficacy Trial of The Toolkit for Optimal Recovery After Concussion (An efficacy tr)
The goal of this study is to test the efficacy of the Toolkit for Optimal Recovery after Concussion (TOR-C), a brief live-video mind-body program. aiming to prevent chronic concussion symptoms and optimize recovery.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Mass General Brigham
-
Contatto:
- Jonathan Greenberg
- Numero di telefono: 617-643-9402
- Email: MGHConcusionToolkit@partners.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Sustained a concussion 3-10 weeks earlier
- At least mild anxiety symptoms (score ≥ 5 on GAD-7 anxiety scale)
- Age 18-35
- English fluency and literacy
- Ability and willingness to participate in study procedures, assessments, and intervention
- Access to a smartphone or computer with internet access
- Cleared for participation by clinic/study staff
Exclusion Criteria:
- Participation in mind-body or CBT treatment in the past 3 months
- Concussion in the past 2 years that resulted in symptoms lasting 3 months or more / current or previous complicated or moderate/severe TBI
- Practice of mindfulness techniques > 45 minutes/week in the past 3 months
- Change in psychotropic medications (e.g., antidepressant, anxiolytics) in the past 6 weeks
- Uncontrolled bipolar disorder, psychosis, active substance dependence, self reported current active suicidal ideation with plan and/or intent
- Pregnancy
- Serious comorbidity expected to worsen in the next 6 months
- Secondary gains that may bias motivation (e.g., pending disability claim)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Toolkit for Optimal Recovery after Concussion (TOR-C)
A 4-week mind-body program delivered via live video (Zoom) 1:1 with a clinician delivering mind-body and cognitive-behavioral skills. |
TOR-C is a brief behavioral mind-body program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It targets anxiety and fear-avoidance factors to prevent chronic concussion symptoms, combining mind-body skills (e.g., mindfulness, deep breathing, acceptance), light cognitive-behavioral skills, skills for gradual return to activity, and concussion psychoeducation. |
|
Comparatore attivo: Health Enhancement after Concussion (HE-C)
A 4-week program delivered via live video (Zoom) 1:1 with a clinician delivering psychoeducation and information about healthy living after a concussion |
HE-C is an attention-matched active control program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It provides general health education after concussion (e.g., sleep, nutrition, physical activity) without the specific skills included in TOR-C. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Post-Concussion Symptom Scale (PCSS)
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of concussion symptoms (e.g., headache, fatigue, dizziness, difficulty concentrating). This is the study's primary outcome; efficacy is judged mainly on reducing these symptoms. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Generalized Anxiety Disorder scale (GAD-7)
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of anxiety symptoms. (Also used at screening, where a score ≥5 is required for eligibility.) |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Patient Health Questionnaire-9 (PHQ-9)
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of depression symptoms. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Fear Avoidance Behavior after Traumatic Brain Injury (FAB-TBI)
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures fear-avoidance behavior, i.e., avoiding activities out of fear they will worsen symptoms. A core mechanism in the fear-avoidance model. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Symptom Catastrophizing Scale
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the tendency to catastrophize concussion symptoms (magnifying, ruminating on, or feeling helpless about them). |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures mindfulness, i.e., present-moment awareness and acceptance of thoughts and feelings. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Behavioral Response to Illness Questionnaire (BRIQ): Limiting behavior subscale
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the tendency to limit or avoid various activities in response to medical conditions |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Pittsburgh Sleep Quality Index (PSQI)
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
An exploratory outcome which measures sleep quality over the past month. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
PROMIS Cognitive Function
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
An exploratory outcome which measures self-reported cognitive function (e.g., perceived problems with memory, attention, and thinking). |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
WHO Disability Assessment Schedule (WHODAS 2.0; 12-item version)
Lasso di tempo: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
It is 12-item measure of health-related functioning and disability across daily activities (e.g., cognition, mobility, self-care, social participation) over the past 30 days, with higher scores indicating greater disability. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Greenberg J, Singh T, Iverson GL, Silverberg ND, Macklin EA, Parker RA, Giacino JT, Yeh GY, Vranceanu AM. A Live Video Mind-Body Treatment to Prevent Persistent Symptoms Following Mild Traumatic Brain Injury: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2021 Jan 14;10(1):e25746. doi: 10.2196/25746.
- Greenberg J, Levey NS, Becker M, Yeh GY, Giacino JT, Iverson G, Silverberg ND, Parker RA, Vranceanu AM. Feasibility Randomized Controlled Trial of the Toolkit for Optimal Recovery After Concussion: A Live Video Program to Prevent Persistent Concussion Symptoms in Young Adults With Anxiety. Arch Phys Med Rehabil. 2025 Apr;106(4):527-536. doi: 10.1016/j.apmr.2024.10.011. Epub 2024 Nov 5.
- Becker ME, Stratton Levey N, Yeh GY, Giacino J, Iverson G, Silverberg N, Parker RA, McKinnon E, Siravo C, Shah P, Vranceanu AM, Greenberg J. Preliminary Feasibility of a Novel Mind-Body Program to Prevent Persistent Concussion Symptoms Among Young Adults With Anxiety: Nonrandomized Open Pilot Study. JMIR Form Res. 2024 Nov 8;8:e64540. doi: 10.2196/64540.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Lesioni cerebrali, traumatiche
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Disordini mentali
- Ferite e lesioni
- Processi patologici
- Trauma craniocerebrale
- Trauma, sistema nervoso
- Lesioni alla testa, chiuso
- Ferite, non penetranti
- Lesioni cerebrali
- Condizioni patologiche, segni e sintomi
- Disturbi d'ansia
- Patologia
- Commozione cerebrale
- Sindrome post-concussione
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2026P002591
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
We plan to share our study protocol, analysis plan, data dictionary, and de-identified data from all measures described under "outcome measures"
Periodo di condivisione IPD
Data from this study will be deposited into the Vivli database no later than one year of the completion of the funded project period
Criteri di accesso alla condivisione IPD
Interested parties can create an account in the Vivli Database and submit a request to access study data
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .